Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 51, Issue 2, 2002, Pages 169-174

  Racette, Susan B ^a   Davis, Ajuah O ^a   McGill, Janet B ^a   Klein, Samuel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; FATTY ACID; GLUCOSE; GLYCEROL; HUMAN INSULIN; INSULIN; ISOPHANE INSULIN; LIPID; LIPOPROTEIN LIPASE; PALMITIC ACID; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME REGULATION; FATTY ACID BLOOD LEVEL; FATTY ACID TRANSPORT; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; KINETICS; LIPID METABOLISM; LIPOLYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036179077     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.29981     Document Type: Article

References (52)

1. Glucose clamp technique: A method for quantifying insulin secretion and resistance
2. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
3. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
4. A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation
5. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
6. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
7. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
8. Troglitazone action is independent of adipose tissue
9. Mechanisms of fatty acid-induced inhibition of glucose uptake
10. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study
11. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat
12. Body composition by DXA: Tried and true?
13. Estimation of adipose tissue mass by magnetic resonance imaging: Validation against dissection in human cadavers
14. Effects of glucagon on free fatty acid metabolism in humans
15. Comparative evaluation of three assay systems for automated determination of hemoglobin A1C
16. Immunoassay of insulin: Two antibody system
17. Determination of free and total insulin and C-peptide in insulin treated diabetics
18. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
19. External and internal standards in the single isotope derivative (radioenzymatic) assay of plasma norepinephrine and epinephrine in normal humans and persons with diabetes mellitus or chronic renal failure
20. Improved accuracy and precision of gas chromatography/mass spectrometry measurements for metabolic tracers
21. Effect of short-term fasting on lipid kinetics in lean and obese women
22. Influences of glucose loading and of injected insulin on hepatic glucose output
23. Regulation of free fatty acid metabolism by insulin in humans: Role of lipolysis and reesterification
24. Effect of fatty acids on glucose production and utilization in man
25. Effect of CS-045 on the activity of insulin receptor kinase in the skeletal muscle of insulin resistant Zucker rats
26. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts
27. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
28. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates
29. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats
30. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
31. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators
32. YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes
33. PPARγ induces the insulin-dependent glucose transporter Glut4 in the absence of C/EBPα during the conversion of 3T3 fibroblasts into adipocytes
34. Interaction between glucose and free fatty acid metabolism in human skeletal muscle
35. Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia
36. Effects of a 48-h fat infusion on insulin secretion and glucose utilization
37. Splanchnic insulin metabolism in obesity. Influence of body fat distribution
38. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans
39. Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
40. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group
41. Troglitazone use in insulin-treated type 2 diabetic patients
42. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
43. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM
44. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
45. Impaired glucose tolerance in normalized by treatment with the thiazolidinedione troglitazone
46. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group
47. Effect of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
48. Efficacy of troglitazone on body fat distribution in type 2 diabetes
49. Effect of troglitazone on body fat distribution in type 2 diabetic patients
50. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes
51. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells
52. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats